key: cord-0763437-3aoxplp3
authors: Kontou, Panagiota I.; Braliou, Georgia G.; Dimou, Niki L.; Nikolopoulos, Georgios; Bagos, Pantelis G.
title: Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis
date: 2020-05-19
journal: Diagnostics (Basel)
DOI: 10.3390/diagnostics10050319
sha: 65aa04e87ad3d1509a37a38c56343157e475140c
doc_id: 763437
cord_uid: 3aoxplp3

The emergence of Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 made imperative the need for diagnostic tests that can identify the infection. Although Nucleic Acid Test (NAT) is considered to be the gold standard, serological tests based on antibodies could be very helpful. However, individual studies are usually inconclusive, thus, a comparison of different tests is needed. We performed a systematic review and meta-analysis in PubMed, medRxiv and bioRxiv. We used the bivariate method for meta-analysis of diagnostic tests pooling sensitivities and specificities. We evaluated IgM and IgG tests based on Enzyme-linked immunosorbent assay (ELISA), Chemiluminescence Enzyme Immunoassays (CLIA), Fluorescence Immunoassays (FIA), and the Lateral Flow Immunoassays (LFIA). We identified 38 studies containing data from 7848 individuals. Tests using the S antigen are more sensitive than N antigen-based tests. IgG tests perform better compared to IgM ones and show better sensitivity when the samples were taken longer after the onset of symptoms. Moreover, a combined IgG/IgM test seems to be a better choice in terms of sensitivity than measuring either antibody alone. All methods yield high specificity with some of them (ELISA and LFIA) reaching levels around 99%. ELISA- and CLIA-based methods perform better in terms of sensitivity (90%–94%) followed by LFIA and FIA with sensitivities ranging from 80% to 89%. ELISA tests could be a safer choice at this stage of the pandemic. LFIA tests are more attractive for large seroprevalence studies but show lower sensitivity, and this should be taken into account when designing and performing seroprevalence studies.

In December 2019, a pneumonia outbreak occurred in Wuhan in China due to a new coronavirus that was later officially named SARS-CoV-2 by the World Health Organization (WHO) [1, 2] . The disease rapidly spread worldwide, and on February 24, WHO declared COVID-19 (coronavirus disease 2019) a pandemic [3] . SARS-CoV-2 shares pathogenicity features with the human coronaviruses SARS-CoV and MERS-CoV [4] , but the incubation period is longer (up to 14 days) [3] . Most patients exhibit mild symptoms, and only a few cases progress to severe or critical disease. Risk factors for severe disease include older age [5] and comorbidities such as hypertension, diabetes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease [6] , whereas a higher incidence in males has also been reported [7] .

For conducting the systematic review and the meta-analysis we followed the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines [23] and the advises for best practices [24] . We conducted the literature search using PubMed (https://www.ncbi.nlm.nih.gov/ pubmed/), medRxiv (https://medrxiv.org/) and bioRxiv (https://www.biorxiv.org/). The search terms used were (SARS-CoV-2 OR "Coronavirus disease 2019" OR COVID-19) AND (IgM OR IgG or antibodies OR antibody OR ELISA or "rapid test"). The references of selected articles were also searched. The searches were concluded by April 17, 2020 , and four different researchers independently evaluated search results. Disagreements in the initial evaluation were resolved by consensus. We did not impose language criteria and included studies written in English and Chinese. We required that eligible studies met the following criteria: (a) COVID-19 cases (SARS-CoV-2 infection) were confirmed either by NAT such as RT-PCR or sequencing or by a combination of NAT and clinical findings and (b) measurements of IgM and/or IgG antibodies were obtained with the use of any of the available methods. We considered eligible studies reporting the comparison of COVID-19 cases against non COVID-19 individuals, as well as case series reporting data only from COVID-19 patients. Data extracted for each study included (if available): first author's last name, percentage of male patients, mean age of COVID-19 patients, mean number of days from onset, and percentage of severe or critically ill COVID-19 patients. In addition, the different bioanalytical methods used for detection and determination of IgG and IgM were also recorded, along with the antigen used to detect the antibodies. In order to construct the 2 × 2 contingency table and obtain estimates for sensitivity and specificity, we recorded the numbers of true positive (TP), false positive (FP), true negative (TN), and false negative (FN) for each study. For studies reporting only COVID-19 patients, we recorded only TP and FN.

The immunoassay methods used for COVID-19 antibody (Ab) detection in all studies included in the present meta-analysis comprise enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassays (CLIA), fluorescence immunoassays (FIA), and the point-of-care (POC) lateral flow immunoassays (LFIA) that are based on immunochromatography [25] [26] [27] [28] [29] . All methods were created to detect IgG and/or IgM antibodies (and in few cases total antibodies) [30] [31] [32] against S (mainly RBD) and/or N viral proteins of human sera/blood samples. For detection of IgM with ELISA, the µ-chain capture principle was used. Plates were firstly coated with mouse anti-human IgM (µ chain) monoclonal antibody. Diluted serum samples (heat-inactivated) together with positive and negative controls were added into the pre-coated plates according to individuals' protocols and incubated at 37 • C for usually 1 h. Washing followed, and horse radish peroxidase (HRP) conjugated recombinant protein of SARS-CoV-2 (rN or rS produced in-house or obtained from a company) was added. After incubation of plates at 37 • C and washes, Tetramethylbenzidine (TMB) substrate solution and the corresponding buffer were added followed by incubation at 37 • C. The reactions were terminated by sulfuric acid addition and the absorbance values at 450 nm (A 450 ) were determined. Usually, the cut off values were calculated by sum and average A 450 of negative control replicates. The principle for the detection of IgG was indirect ELISA, where serum sample dilutions (plus positive and negative controls) were added to previously coated with rN or rS protein ELISA plates. Subsequently, incubation and washes were performed, and HRP-conjugated mouse anti-human IgG monoclonal antibody was added into the plates. Absorbance values at 450 nm were measured for detection. The cut off value was calculated by the sum and average A 450 of negative control replicates [27] .

LFIA is a rapid method based on immunochromatography, which uses colloidal gold conjugated COVID-19 antigens. It comprises a plastic pad where a nitrocellulose membrane is fitted. Three separate lines are created by immobilizing goat anti-human IgM, IgG, and goat anti-rabbit-IgG at test M, G, and control (C) lines, respectively. The entire conjugate pad is sprayed with a mixture of AuNP-COVID-19 recombinant antigen conjugate (colloidal-gold pretreated with SARS-CoV-2 recombinant protein) and AuNP-rabbit-IgG. Sample is applied to the sample pad and with the aid of a buffer migrates towards the immobilized lines of antibodies spread with the AuNP-recombinant antigen. When a reaction occurs, a visible line is formed suggesting the existence of IgM and IgG. It should be noted that color in the control line should be formed for a test to be valid [26, 33] . The test gives qualitative results that are judged by optical inspection, usually 15 min after sample application. In some LFIAs purchased from companies, the specific antigen that LFIA was based on was not reported. Since most of the companies provide combined N-and S-based LFIAs, we assumed that in unspecified cases the LFIAs were Nand S-based.

CLIA is a chemiluminescence-based assay, mainly developed by companies. The detection of IgG or IgM is based on double-antibodies sandwich immunoassay. Recombinant antigens rN and rS are conjugated with fluorescein isothiocyanate (FITC) and immobilized on the anti-FITC antibody conjugated magnetic particles. Alkaline phosphatase conjugated human IgG/IgM antibody is used as the detection antibody. An automated magnetic chemiluminescence analyzer is needed to read the measured values of chemiluminescence, and results are given as arbitrary units. As threshold, 10 AU/mL is usually used for both IgM and IgG and according to manufacturer recommendations [34] . The analyzer can be batch and random access with the possibility to give results within half an hour at best [34, 35] . Because in most cases CLIA detected both anti-N and anti-S IgG and IgM antibodies (with With FIA, we denote fluorescence immunoassays that can be performed on multi-test cover slides [36] or be based on fluorescence immunochromatography (AIE/Quantum dot-based fluorescence immunochromatographic assay, AFIA) [37, 38] . The latter can be rapid, but all fluorescence-based immunoassays need analyzers to read the results [38] .

We performed a quality assessment of the included studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool, offered by the Review Manager Software (RevMan 5.2.3) ( Table S1 ). The QUADAS is a quality assessment tool specifically developed for systematic reviews of diagnostic accuracy studies and consists of four key domains: patient selection, index test, reference standard, and flow and timing; each domain is rated as low risk, high risk and unclear risk (Table S2, Figure S1 ).

We used the bivariate meta-analytic method modified for the meta-analysis of diagnostic tests [39] . The method has been shown to be equivalent to the so-called hsROC method [40, 41] and uses logit-transforms of TPR (true positive rate) and FPR (false positive rate) in order to model Sensitivity and Specificity, as well as to account for the between-studies variability (heterogeneity). Studies that include information only for logit (TPR) are included under the missing at random assumptions in order to maximize the sample and allow for modelling the between-studies variability and correlation. The Begg's rank correlation test [42] and the Egger's regression test [43] were used on logit (TPR) to evaluate possible publication bias. The analysis was performed using Stata 13 (Stata Corporation, College Station, TX, USA) and the command "mvmeta" with the method of moments for multivariate meta-analysis and meta-regression [44] . Statistical significance was set at p < 0.05. Meta-analysis was performed in cases where two or more studies were available whereas meta-regression and tests for publication bias where 5 or more studies were available.

The electronic search revealed 115 articles from PubMed, 72 from medRxiv and 12 from bioRxiv, from which we identified 38 eligible studies after scrutiny [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] (Figure 1 ). These include in total 7848 individuals (3522 COVID-19 cases and 4326 healthy, or non COVID-19, individuals). A total of 21 studies reported data for both COVID-19 cases and controls, whereas 17 studies reported data only for COVID-19 cases (Table 1) . A total of 13 studies used RT-PCR or other nucleic acid-based tests (NATs) as the gold standard for case ascertainment, whereas 25 studies ascertained COVID-19 cases using a combination of molecular and clinical features. We built our analysis on grouping the tests according to the method and the specific antigen used. Because we found kits and reagents from 25 different companies, plus the various in-house tests developed for research purposes, stratification according to different kits was pointless. Several studies reported the results of multiple tests on the same individuals; however, they were not included in the same meta-analysis since we analyzed each test separately. In one study that compared several different LFIA tests, we used the results of the one with the median performance (even though the differences were small). Other studies reported samples from multiple populations, and in such cases, they were considered distinct.

14 studies in total reported results from ELISA-based tests (detecting anti-N or anti-S IgG, IgM antibodies, or both). S-based ELISAs, in general, perform better compared to those based on N antigen. IgG and IgM seem to perform similarly, but the combination of IgG and IgM seems to be superior leading to a sensitivity of 0.935 (95% CI: 0.900, 0.971) ( Figure 1 ). All ELISA-based methods seem to have rather high specificities (ranging from 0.961 to 0.995). Meta-regression analysis showed that the mean number of days from disease onset and the proportion of severe/critical patients have an influence on the overall sensitivity of the IgG tests. Both Egger's and Begg's tests did not detect publication bias or other small study effects. days from disease onset influences the overall outcome in the IgG and IgG/IgM tests. Both Egger's and Begg's tests could not find evidence for publication bias or other small study effects.

Lastly, FIA-based tests were found in three studies using a combination of N and S antigens. Both IgG and IgM show similar sensitivities (~0.86) and specificities (0.95) (Figure 2, Figure 3) ; however, the sample is small (3 studies, 327 patients). Due to the small number of studies, tests for publication bias or meta-regression could not be applied. CLIA-based tests were used in 13 studies. In all cases IgGs and IgMs were investigated. In this analysis, we also pooled together the studies that considered NS antigens with the studies that used N antigen. The sensitivities of detecting IgG seem to be better compared to that of IgM (0.944 vs. 0.810). Combining IgM and IgG yields a slightly worse sensitivity (0.907, 95% CI: 0.753, 1.000), but this estimate arises from only two studies (970 patients) and thus has large uncertainty ( Figure 1 ). Specificities range from 0.954 to 0.984. Meta-regression analysis revealed that the mean number of days from disease onset has an influence on the overall outcome in the IgG tests. The Begg's test provided some evidence for publication bias in the IgG analysis.

13 studies reported results from LFIA-based tests. The majority of the tests identified antibodies against both N and S antigens, and results were obtained for both IgG and IgM. In this analysis, we also pooled together the studies that considered NS antigens with the studies that used S antigen. IgG and IgM seem to perform comparably but rather low since the sensitivities range from 0.53 to 0.66. Combining IgG and IgM yields better estimates (0.78-0.83) but still with lower sensitivity compared to ELISA-and CLIA-based tests (Figure 1 ). Specificity in all cases ranged from 0.914 to 0.994. In the largest overall analysis, pooling together the 11 studies that used N, S, or NS antigens, the combination of IgG and IgM antibodies yields a sensitivity of 0.800 (95% CI: 0.663, 0.935) and specificity of 0.984 (95%CI: 0.969, 0.999). Meta-regression analysis revealed that the mean number of days from disease onset influences the overall outcome in the IgG and IgG/IgM tests. Both Egger's and Begg's tests could not find evidence for publication bias or other small study effects.

Lastly, FIA-based tests were found in three studies using a combination of N and S antigens. Both IgG and IgM show similar sensitivities (~0.86) and specificities (0.95) (Figure 2, Figure 3) ; however, the sample is small (3 studies, 327 patients). Due to the small number of studies, tests for publication bias or meta-regression could not be applied. Table 2 and the Results section. Table 2 and the Results section. Table 2 and the Results section. Table 2 and the Results section. Table 2 and the Results section. Table 2 and the Results section. Table 2 . Results of the meta-analysis for the different types of antibody tests. We list the characteristics of the included studies, the pooled sensitivity and specificity along with the 95% confidence intervals, the variables that were found statistically significant in meta-regression, and the results of the tests for publication bias. For the description of the test, the antibodies (Ab) and antigens (Ag), see Methods section (mdfo: mean days from onset; severe: percent of patients with severe or critical condition; NA: not applicable). N: nucleocapsid protein, S: spike protein, NS: nucleocapsid and Spike proteins. 

Non-pharmaceutical interventions including increased testing rates, contact tracing, school closures, ban of mass gatherings, physical distancing, restriction of movement, and cordon sanitaire were effective in reducing transmission rates of SARS-CoV-2 in Wuhan, China, and other settings [69] . However, this type of intervention has tremendous societal and economic consequences potentially resulting in social disorganization and great recession. One approach to de-escalating public health measures and returning to a state of normalcy, while maintaining epidemiological vigilance and ability to respond fast to viral resurgence, is to identify people with immunity to SARS-CoV-2 and estimate their proportion in the entire population. This approach would indicate immune people including health-care workers who can go back to work without risking their health or that of others, help reopen borders, and monitor the development of herd immunity. Unfortunately, human immune response to the new pathogen is not well studied yet. The serological tests that have recently been developed employ different methods and target either IgG or IgM or both. In an attempt to fill the knowledge gap, this systematic review summarized evidence from 38 studies involving 7848 individuals. Although the US Food and Drug Administration (FDA) has approved ELISA, LFIA, and neutralization assays, we included in the present meta-analysis studies using CLIA and FIA methods as well, because they can potentially be approved in the future. We did not consider neutralization assays since they are more time demanding (3-5 days) and can only be performed in laboratories of Biosafety Level-3 (BSL-3) [70] . The meta-analysis showed that all methods yielded high specificity with some of the methods (ELISA and LFIA) reaching levels higher than 99%. ELISA-and CLIA-based methods performed better in terms of sensitivity (90-96%) followed by LFIA and FIA with sensitivities ranging from 80% to 89%.

Sample quality, low antibody concentrations, and especially timing of the test-too soon after a person is infected when antibodies have not been developed yet or too late when IgM antibodies have decreased or disappeared-could potentially explain the low ability of the antibody tests to identify people with COVID-19 [70] . According to kinetic measurements of some of the included studies [22, 50, 55] IgM peaks between days 5 and 12 and then drops slowly. IgGs reach peak concentrations after day 20 or so as IgM antibodies disappear. This meta-analysis showed, through meta-regression, that IgG tests did have better sensitivity when the samples were taken after the first week that follows the onset of symptoms. This is further corroborated by the lower specificity of IgM antibodies compared to IgG [15] . Only few of the included studies provided data stratified by the time of onset of symptoms, so a separate stratified analysis was not feasible, but this should be a goal for future studies. In any case, care should be paid when antibody tests are used in the first week after the onset of disease symptoms. Moreover, irrespective of the method, a combined IgG/IgM test seems to be a better choice in terms of sensitivity than measuring either antibody type alone. The analyses also showed that tests that use the S antigen are more sensitive than N antigen-based ELISA tests, probably due to higher sensitivity and earlier immune response to the S antigen [53] and more specific perhaps due to lower cross-reactivity with less conserved regions of spike proteins existing in other coronaviruses (SARS-CoV) [17, 56, 64] . Finally, despite the suboptimal sensitivity, antibody tests could certainly supplement NATs in the diagnosis of people with suspected SARS-CoV-2 infection [65] . In any case, a direct comparison of antibody tests against NATs is also needed in future studies (in the current review only a handful of studies performed this, and they did that only in COVID-19 patients).

Antibody tests for SARS-CoV-2 have other accuracy issues that deserve attention and further assessment. For instance, cross-reaction with human endemic coronaviruses could make antibody tests less specific and produce false positive results [30, 35, 56, 63] . A low specificity may have important consequences both in terms of diagnosis and population surveillance. At the individual level, false positive results pose risks as people who have never been infected are perhaps allowed to work or travel because they are considered immune. At a population level and regarding epidemiological studies, given the low prevalence of SARS-CoV-2 in most settings at the moment, false positives may inflate prevalence estimates and give a distorted picture of lower mortality rate and higher population immunity than what is in reality. On the other hand, low sensitivity may result in falsely assuming that a person is not infected and consequently jeopardizing measures to prevent the spread of the epidemic. Based on the results of this meta-analysis, ELISA tests that achieved specificity higher than 99% and sensitivity~93% could be the safer choice at this stage of the pandemic. CLIA tests show comparable sensitivity (~90%) but slightly decreased specificity (95-98%). LFIA tests on the other hand are particularly attractive for large seroprevalence studies and can be used as POC tests. They show high specificity, comparable to ELISA (~99%), but lower sensitivity (~80%), and these estimates should be taken into account when designing and performing seroprevalence studies, for instance, by adjusting properly the obtained positive and negative findings. At the individual level, perhaps mixed strategies could be adopted (for instance re-testing a negative finding using a different test).

Of note, even if tests are highly accurate, much about protective immunity is unknown, and the true presence of binding antibodies might not mean that people have indeed developed high titers of neutralizing antibodies and are thus immune to re-infection [71] . Research on Rhesus macaques infected with SARS-CoV-2 was promising though showing that reinfection did not occur following rechallenge with the same dose of SARS-CoV-2 strain [72] . Finally, viral load does not decline rapidly after seroconversion and people may remain infectious despite being truly positive in antibodies tests [36] .

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster

A new coronavirus associated with human respiratory disease in China

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV

A geroscience perspective on COVID-19 mortality

Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis

Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Origin and evolution of pathogenic coronaviruses

Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding

Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Modular organization of SARS coronavirus nucleocapsid protein

Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein

The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

COVID-19) Pandemic: Increased Transmission in the EU/EEA and the UK-Sixth Update-12

The standard coronavirus test, if available, works well-But can new diagnostics help in this pandemic? ScienceMag 2020

First Case of 2019 Novel Coronavirus in the United States

Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

Ten simple rules for carrying out and writing meta-analyses

Detection of antibodies against SARS-CoV-2 in patients with COVID-19

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis

Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold-Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19)

Profile of Specific Antibodies to SARS-CoV-2: The First Report

Evaluation of nine commercial SARS-CoV-2 immunoassays

Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset

Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19

Dynamic profile of severe or critical COVID-19 cases

Elevated serum IgM levels indicate poor outcome in patients with coronavirus disease 2019 pneumonia: A retrospective case-control study

Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak

Virological assessment of hospitalized patients with COVID-2019

Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2. medRxiv 2020

Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection

A bivariate approach to meta-analysis

Bivariate random effects meta-analysis of ROC curves

A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard

Operating characteristics of a rank correlation test for publication bias

Bias in meta-analysis detected by a simple, graphical test

Multivariate random-effects meta-regression: Updates to mvmeta

Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province

COVID-19 Antibody Seroprevalence in

Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department

Evaluation the auxiliary diagnosis value of antibodies assays for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19)

Rapid diagnosis of SARS-CoV-2 infection by detecting IgG and IgM antibodies with an immunochromatographic device: A prospective single-center study

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2

Diagnostic Indexes of a Rapid IgG/IgM Combined Antibody Test for SARS-CoV-2. medRxiv 2020

Antibody responses to SARS-CoV-2 in COVID-19 patients: The perspective application of serological tests in clinical practice

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease

Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Clinical meanings of rapid serological assay in patients tested for SARS-Co2 RT-PCR

Viral Kinetics and Antibody Responses in Patients with COVID-19

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study

Antibodies in Infants Born to Mothers With COVID-19 Pneumonia

Re: Profile of specific antibodies to SARS-CoV-2: The first report

Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing

Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19)

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-expressed full-length SARS-CoV-2 S1 proteins

Risk-adapted Treatment Strategy For COVID-19 Patients

Detection of serum IgM and IgG for COVID-19 diagnosis

Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China

Interpreting Diagnostic Tests for SARS-CoV-2

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques